AdvancingPlasmodium vivaxmalaria treatment in India: The vital role of glucose 6-phosphate dehydrogenase point-of-care tests

Conflict of interest statement

The authors declare that there is no conflict of interests.

Funding

The authors received no extramural funding for the study.

Authors’ contributions

NN and PKB did the literature search and drafted the manuscript; NN, and PKB gave intellectual comments, and reviewed the final version.

Publisher’s note

The Publisher of the Journal remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Edited by Zhang Q, Lei Y, Pan Y

Acknowledgements

The authors would like to thank ICMR-NIMR, Delhi for the institutional support.

References

[1] Mayence A, Vanden Eynde JJ. Tafenoquine: A 2018 novel FDA-approved prodrug for the radical cure of Plasmodium vivax malaria and prophylaxis of malaria. Pharm Basel Switz 2019; 12(3): 115.

[2] Mehdipour P, Rajasekhar M, Dini S, Zaloumis S, Abreha T, Adam I, et al. Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: A WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. Malar J 2023; 22(1): 306.

[3] Verma R, Commons RJ, Gupta A, Rahi M, Bharti PK, Thriemer K, et al. Safety and efficacy of primaquine in patients with Plasmodium vivax malaria from South Asia: A systematic review and individual patient data meta-analysis. BMJ Glob Health 2023; 8(12): e012675.

[4] Mukherjee MB, Colah RB, Martin S, Ghosh K. Glucose-6-phosphate dehydrogenase (G6PD) deficiency among tribal populations of India-Country scenario. Indian J Med Res 2015; 141(5): 516-520.

[5] Ahmad SS, Verma R, Commons RJ, Nitika , Singh-Phulgenda S, Chhajed R, et al. A randomised controlled trial to compare the efficacy, safety, and tolerability of low dose, short course primaquine in adults with uncomplicated P.vivax malaria in two hospitals in India. Trials 2024; 25(1): 154.

[6] Brito-Sousa JD, Santos TC, Avalos S, Fontecha G, Melo GC, Val F, et al. Clinical spectrum of primaquine-induced hemolysis in glucose-6-phosphate dehydrogenase deficiency: A 9-year hospitalization-based study from the Brazilian Amazon. Clin Infect Dis Off Publ Infect Dis Soc Am 2019; 69(8): 1440-1442.

[7] Sadhewa A, Satyagraha AW, Alam MS, Adissu W, Anvikar A, Bancone G, et al. Performance of quantitative point-of-care tests to measure G6PD activity: An individual participant data meta-analysis. PLoS Negl Trop Dis 2025; 19(3): e0012864.